Investment Rating - The report maintains a "Buy" rating for the company [10] Core Views - In the first half of 2025, the company achieved operating revenue of 3.188 billion yuan, a year-on-year increase of 18.20%, and a net profit attributable to shareholders of 617 million yuan, up 23.71% year-on-year, indicating a significant profit growth rate surpassing revenue growth [5][6] - The small molecule CDMO business generated revenue of 2.429 billion yuan, growing by 10.6%, with a gross margin of 47.8%, benefiting from improved operational efficiency and cost control [6] - Emerging businesses continued to grow rapidly, with revenue of 756 million yuan, an increase of 51.22%, and a gross margin of 29.79%, with a backlog of orders increasing by over 40% year-on-year [7] - The company is accelerating global market expansion, with revenue from the US market at 1.789 billion yuan (up 0.45%), Europe at 548 million yuan (up 200%), and domestic market at 713 million yuan (up 3.44%) [8] Summary by Sections Financial Performance - The company reported a significant increase in both revenue and net profit in the first half of 2025, with revenue of 3.188 billion yuan and net profit of 617 million yuan, reflecting strong operational performance [5][6] - The projected revenue for 2025-2027 is 6.683 billion yuan, 7.623 billion yuan, and 8.758 billion yuan, with year-on-year growth rates of 15.1%, 14.1%, and 14.9% respectively [9] Business Segments - The small molecule CDMO segment is expected to maintain steady growth with 11 PPQ projects anticipated in the second half of 2025 [6] - The emerging business segment, particularly the chemical macromolecule business, is projected to continue its rapid growth, with expected revenue growth exceeding 130% year-on-year [7] Market Expansion - The company is making strides in global market expansion, with significant revenue growth in Europe and stable performance in the US and domestic markets [8]